HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence - PubMed
5 hours ago
- #immunotherapy resistance
- #YAP
- #HDAC inhibitors
- High YAP expression in NSCLC is linked to poor immunotherapy outcomes and is a better predictor than PD-L1.
- Tucidinostat (TD) inhibits YAP activity by suppressing expression through SNAI2-mediated epigenetic regulation.
- Combining TD with ICIs successfully reversed acquired immunotherapy resistance in two advanced NSCLC patients with high YAP.
- The study suggests YAP as a key biomarker and TD+ICI as a potential strategy to overcome YAP-driven immune resistance.